Diclazuril (Protazil) - EPM

Diclazuril, marketed under the brand name Protazil, represents one of the FDA-approved treatment options specifically developed for Equine Protozoal Myeloencephalitis in horses. This triazine-class antiprotozoal medication targets the causative organism Sarcocystis neurona, which is responsible for the vast majority of EPM cases diagnosed in North America. The drug has become an important tool in equine medicine since its approval, offering veterinarians and horse owners an effective oral treatment option for this debilitating neurological disease that can significantly impact a horse's quality of life and athletic performance.

The mechanism of action of diclazuril involves disruption of the protozoal parasite's ability to replicate and survive within the horse's central nervous system. Specifically, diclazuril interferes with the parasite's mitochondrial electron transport chain and disrupts essential metabolic pathways required for the organism's survival. This targeted approach allows the drug to effectively combat the infection while maintaining a favorable safety profile in equine patients. The medication works by inhibiting the development of the parasite's schizont stage, preventing further neurological damage and allowing the horse's immune system to clear the infection over time.

Protazil is formulated as alfalfa-based oral pellets, which represents a significant advantage in terms of palatability and ease of administration compared to some other EPM treatments. The pellet formulation can be top-dressed on the horse's regular feed, making daily administration straightforward for most horse owners. Each pellet is designed to deliver a precise dose based on the horse's body weight, and the once-daily dosing schedule helps ensure compliance throughout the treatment period. The familiar alfalfa base encourages horses to consume the medication readily, reducing the challenges often associated with medicating horses over extended treatment courses.

As with all antiprotozoal medications for EPM, diclazuril therapy requires careful veterinary supervision from diagnosis through the completion of treatment and follow-up neurological evaluations. Accurate diagnosis of EPM is essential before initiating treatment, as the clinical signs can mimic other neurological conditions affecting horses. Veterinarians typically confirm the diagnosis through a combination of clinical examination, cerebrospinal fluid analysis, and serological testing. The importance of completing the full prescribed treatment course cannot be overstated, as premature discontinuation may allow the parasite to persist and neurological deficits to progress.

The primary and FDA-approved indication for diclazuril is the treatment of Equine Protozoal Myeloencephalitis caused by Sarcocystis neurona infection. EPM remains one of the most significant neurological diseases affecting horses in the Americas, with prevalence varying by geographic region and exposure to the definitive host, the opossum. The disease occurs when horses inadvertently ingest sporocysts shed in opossum feces, typically through contaminated feed or water sources. Once ingested, the parasites migrate to the central nervous system where they cause progressive neurological damage if left untreated. Diclazuril's specific activity against this organism makes it a targeted treatment option for affected horses.

Clinical presentations of EPM that warrant diclazuril treatment vary widely depending on which areas of the central nervous system are affected by the parasitic infection. Commonly observed signs include asymmetric gait abnormalities, muscle atrophy often affecting the hindquarters more severely, incoordination, weakness in one or more limbs, and changes in behavior or mentation. Some horses present with acute onset of severe neurological deficits, while others show gradual, progressive deterioration over weeks to months. Horses of any age, breed, or discipline may be affected, though stress factors such as heavy training, transport, concurrent illness, or other immunocompromising conditions may increase susceptibility to clinical disease following exposure.

Performance horses diagnosed with EPM represent a significant portion of diclazuril-treated cases, as the neurological deficits caused by this disease directly impact athletic ability and safety under saddle. Event horses, dressage horses, show jumpers, and racing Thoroughbreds and Standardbreds all may develop EPM with career-threatening consequences if not appropriately treated. The goal of therapy is not only to eliminate the active infection but also to maximize neurological recovery, which depends on the extent of central nervous system damage present at the time treatment is initiated. Early diagnosis and prompt treatment with diclazuril generally correlate with better outcomes.

Diclazuril is sometimes selected over other FDA-approved EPM treatments based on specific case factors and veterinary preference. The once-daily dosing schedule and palatable pellet formulation may offer advantages for horses that are difficult to medicate or for situations where caregiver compliance is a concern. Some veterinarians prefer diclazuril for horses that have shown adverse reactions to other antiprotozoal agents or when drug interactions with concurrent medications are a consideration. The choice of EPM treatment should always be made in consultation with a veterinarian who can evaluate the individual horse's condition, medical history, and specific circumstances.

While diclazuril is specifically labeled for Sarcocystis neurona infections, the clinical reality is that a small percentage of EPM cases are caused by Neospora hughesi, a related protozoal organism. The efficacy of diclazuril against Neospora hughesi is less well-established than its activity against Sarcocystis neurona, and veterinarians may consider alternative treatment protocols or combination approaches for confirmed or suspected Neospora cases. Accurate identification of the causative organism through appropriate diagnostic testing helps guide treatment decisions and set realistic expectations for therapeutic outcomes.

The dosing protocol for diclazuril in horses requires careful consideration of the individual patient's body weight and should always be determined by a licensed veterinarian familiar with the case. Protazil is available as a top-dress pellet formulation, with each container providing sufficient medication for a complete treatment course at the labeled dose rate. Accurate weight determination is critical for appropriate dosing, as underdosing may result in treatment failure while overdosing increases the risk of adverse effects. Weight tapes provide reasonable estimates for most horses, though livestock scales offer greater precision when available, particularly for horses at the extremes of the size range.

The standard labeled dosing for Protazil calls for administration at a rate of 1 mg per kilogram of body weight, given once daily for 28 consecutive days. This translates to approximately 0.45 mg per pound of body weight. The alfalfa-based pellets are designed to be top-dressed on the horse's regular grain ration, and most horses consume the medication readily without requiring special palatability measures. For horses that are hesitant to eat medicated feed, adding a small amount of molasses or mixing the pellets with a favored treat may improve acceptance. The entire dose should be consumed at each administration to ensure therapeutic drug levels are maintained throughout the treatment period.

The 28-day treatment duration represents the minimum course established during FDA approval studies and should be completed in full even if clinical improvement is observed before that time. Some veterinarians may extend treatment beyond 28 days in severe cases or when neurological improvement plateaus before full resolution of clinical signs. The decision to extend therapy should be made by the attending veterinarian based on ongoing neurological examinations and response to treatment. Prematurely discontinuing treatment may allow residual parasites to persist and potentially cause disease relapse or continued neurological deterioration.

Administration timing should be consistent from day to day, ideally at the same time each morning or evening to maintain steady drug levels. The medication can be given with or without food, though the pellet formulation is specifically designed for mixing with feed. Horses should have access to fresh water at all times during treatment. If treatment is being administered by barn staff or multiple caregivers, clear communication and record-keeping help ensure no doses are missed and the treatment schedule remains on track throughout the 28-day course.

Missed doses should be addressed by giving the medication as soon as the oversight is recognized, then returning to the regular dosing schedule. If a dose is missed entirely and discovered close to the next scheduled administration time, the missed dose should generally be skipped rather than doubled. Never administer double doses of diclazuril in an attempt to make up for missed medications, as this increases the risk of adverse effects without providing additional therapeutic benefit. If multiple doses are missed, contact the prescribing veterinarian for guidance on whether to extend the treatment course or adjust the protocol.

Completion of the full treatment course is essential for maximizing the chances of successful EPM treatment and minimizing the risk of relapse. Horse owners should understand from the outset that 28 days represents a significant commitment, and arrangements should be made to ensure consistent daily administration throughout this period. Following completion of treatment, veterinary re-evaluation is recommended to assess neurological status and determine whether additional therapy or supportive care measures are indicated. Some horses show dramatic improvement during treatment, while others require extended recovery periods before reaching their maximum level of neurological function.

Diclazuril is generally well-tolerated by most horses when administered according to label directions under veterinary supervision. Clinical trials conducted for FDA approval demonstrated an acceptable safety profile, with the majority of treated horses completing the full course without significant adverse events. However, as with any medication, individual horses may experience side effects ranging from mild and self-limiting to more serious reactions requiring veterinary attention. Horse owners should be familiar with potential adverse effects and monitor their horses carefully throughout the treatment period.

The most commonly reported side effects associated with diclazuril therapy involve the gastrointestinal system. Some horses may experience mild loose stools or changes in manure consistency during the treatment period. Decreased appetite or transient feed refusal has been observed in some cases, which may be related to the medication itself or to the stress of illness and treatment. These gastrointestinal effects are typically mild and resolve without intervention, though affected horses should be monitored to ensure they continue eating and drinking adequately. If appetite loss persists for more than 24 to 48 hours or is accompanied by signs of colic, veterinary consultation is warranted.

Lethargy and mild depression have been noted in some horses receiving diclazuril, though distinguishing medication-related effects from signs of the underlying EPM infection can be challenging. Horses with EPM often display behavior changes as part of their disease process, and sorting out what is attributable to the disease versus the treatment requires careful observation and veterinary assessment. Any significant change in mentation, severe depression, or signs suggestive of worsening neurological function should prompt immediate veterinary evaluation to rule out disease progression or adverse drug reactions.

Serious adverse reactions to diclazuril are uncommon but have been reported. Signs of potential allergic or hypersensitivity reactions may include hives, facial swelling, difficulty breathing, or acute onset of severe gastrointestinal distress. These reactions require immediate veterinary attention and typically necessitate discontinuation of the medication. Horses that experience allergic reactions to diclazuril should not receive the drug again, and alternative EPM treatments should be discussed with the veterinarian. Any reaction that seems severe or is causing significant distress to the horse warrants emergency veterinary consultation.

Long-term effects of diclazuril administration have not been extensively studied, as the drug is intended for a defined 28-day treatment course rather than chronic use. Horses receiving extended treatment courses beyond the labeled duration should be monitored more closely for any emerging adverse effects. Periodic bloodwork to assess liver and kidney function may be recommended by some veterinarians for horses receiving prolonged therapy, though specific monitoring protocols have not been established. Any concerns about adverse effects should be discussed promptly with the prescribing veterinarian, who can help determine whether observed changes are likely medication-related and whether treatment modifications are indicated.

Diclazuril should not be administered to horses with known hypersensitivity or allergic reactions to the drug or other triazine-class compounds. Previous adverse reactions to diclazuril, regardless of severity, represent an absolute contraindication for future use, and alternative EPM treatments should be selected for such horses. Horse owners should inform their veterinarian of any known drug allergies or previous adverse medication reactions before initiating EPM treatment. Cross-reactivity between triazine compounds is possible, so horses with reactions to related drugs should be treated with caution.

Significant hepatic impairment represents a relative contraindication for diclazuril use, as the drug is metabolized by the liver and altered hepatic function may affect drug clearance and increase the risk of adverse effects. Horses with known liver disease, elevated liver enzymes, or other indicators of hepatic dysfunction should be thoroughly evaluated before starting diclazuril therapy. Baseline bloodwork including hepatic function parameters may be recommended for horses with suspected or confirmed liver compromise. Alternative treatment approaches or adjusted dosing regimens may be necessary for horses with significant hepatic impairment.

The safety of diclazuril in pregnant mares has not been established through controlled studies, and the drug should be used with caution in breeding animals. The decision to treat a pregnant mare with EPM must weigh the risks of the disease against potential effects on the developing foal. EPM itself can be severely debilitating or life-threatening, which may justify treatment despite limited safety data in pregnancy. Similarly, the safety of diclazuril in lactating mares has not been fully characterized, and nursing foals may be exposed to the drug through milk. Veterinary consultation is essential for determining the most appropriate course of action for pregnant or nursing mares diagnosed with EPM.

Horses with severe debilitation, concurrent serious illness, or significantly compromised immune function require careful evaluation before initiating diclazuril treatment. While EPM often occurs in stressed or immunocompromised horses, the presence of additional disease conditions may complicate treatment and affect drug tolerance. Horses receiving concurrent medications should have potential drug interactions evaluated before adding diclazuril to their treatment regimen. Veterinarians may recommend additional monitoring or supportive care measures for horses with complicating health factors. Competition horses require special consideration regarding withdrawal times and regulatory requirements, as discussed in subsequent sections.

The drug interaction profile of diclazuril in horses has not been exhaustively characterized, and veterinarians should carefully evaluate concurrent medications when prescribing this antiprotozoal agent. Horses with EPM often require supportive medications for pain management, inflammation control, or management of secondary complications, making potential interactions a practical clinical concern. While no absolute contraindications for concurrent drug use have been established, certain combinations warrant caution and close monitoring throughout the treatment period.

Non-steroidal anti-inflammatory drugs are frequently used in horses with EPM to manage discomfort and reduce inflammation associated with neurological damage. While specific interactions between diclazuril and common equine NSAIDs such as phenylbutazone or flunixin meglumine have not been documented, concurrent use of multiple medications increases overall hepatic metabolic burden. Horses receiving long-term NSAID therapy alongside diclazuril treatment should be monitored for signs of gastrointestinal upset or hepatic stress. As with all NSAID use in horses, appropriate dosing, duration limits, and gastrointestinal protection measures should be observed.

Corticosteroids are sometimes used as adjunctive therapy in EPM cases to reduce inflammation within the central nervous system, though their use remains somewhat controversial due to potential immunosuppressive effects. If corticosteroids are prescribed alongside diclazuril, careful attention should be paid to the overall treatment plan and monitoring schedule. The immunosuppressive properties of corticosteroids theoretically could affect the horse's ability to clear the protozoal infection, though clinical experience suggests judicious short-term use may be beneficial in select cases. The decision to combine these therapies should be made by the attending veterinarian based on individual case assessment.

Herbal supplements and nutraceuticals commonly used in horses have unknown interaction potential with diclazuril. Many horse owners administer joint supplements, immune-supporting herbs, or other complementary products, and the effects of these substances on diclazuril metabolism or efficacy are not established. While there is no specific evidence of harmful interactions, owners should inform their veterinarian of all products being administered so that the complete treatment picture can be evaluated. Veterinarians may recommend temporarily discontinuing non-essential supplements during the EPM treatment period to minimize variables and simplify monitoring for adverse effects.

Veterinary monitoring throughout diclazuril treatment is recommended to assess both the horse's response to therapy and tolerance of the medication. Initial examination should establish baseline neurological status using a standardized grading system, allowing objective assessment of improvement or deterioration during and after treatment. Follow-up examinations during treatment help identify any emerging adverse effects and allow treatment modifications if needed. Bloodwork to evaluate hepatic and renal function may be recommended at baseline and during treatment for horses with predisposing risk factors or those showing signs of potential drug intolerance.

Special precautions apply to certain populations of horses receiving diclazuril. Foals and young horses have not been extensively studied, and dosing and safety information for horses under one year of age are limited. Geriatric horses may have reduced hepatic or renal function that affects drug metabolism and clearance. Horses with Pituitary Pars Intermedia Dysfunction, commonly known as Cushing's disease, often have compromised immune function that both predisposes them to EPM and may affect their response to treatment. These special populations warrant closer monitoring and potentially adjusted treatment approaches under veterinary guidance.

Competition and performance horse owners must be acutely aware that diclazuril may be classified as a prohibited or controlled substance under various regulatory bodies' rules. The FEI, USEF, and state racing commissions maintain lists of prohibited substances with specific detection times and withdrawal guidelines. Detection times do not necessarily equal withdrawal times, and residual drug metabolites may be detectable in blood or urine for extended periods after completing treatment. Horse owners competing under any regulatory body should consult both their veterinarian and the applicable regulatory authority before administering diclazuril to a competition horse. Maintaining detailed treatment records is essential for addressing any regulatory inquiries.

Safe handling of diclazuril requires standard precautions for veterinary medications. While the pellet formulation minimizes dust exposure and handling risks, persons administering the medication should wash hands thoroughly after contact. Pregnant women or individuals with immune compromise should exercise additional caution when handling any antiparasitic medication. The product should be kept in its original container, away from food storage areas, and out of reach of children. Accidental ingestion by humans should prompt consultation with a poison control center or physician.

Long-term considerations for horses completing EPM treatment include ongoing monitoring for disease recurrence and addressing any residual neurological deficits through rehabilitation and supportive care. Some horses recover fully following treatment, while others retain permanent neurological damage depending on the extent of central nervous system involvement at the time of diagnosis. Recurrence of EPM is possible, particularly in horses with ongoing exposure to contaminated environments or compromised immune function. Horse owners should work with their veterinarian to minimize future exposure risk and establish appropriate monitoring schedules for horses with a history of EPM.

Proper storage of diclazuril ensures the medication maintains its stability and effectiveness throughout the treatment period. Protazil pellets should be stored at controlled room temperature, generally between 59 and 86 degrees Fahrenheit (15 to 30 degrees Celsius). The product should be protected from excessive heat, moisture, and direct sunlight, which can degrade the active ingredient and reduce therapeutic efficacy. In barn environments, medication should be stored in a climate-controlled tack room or office area rather than in feed rooms subject to temperature extremes or high humidity.

The container should remain tightly closed when not in use to protect the pellets from moisture absorption and environmental contamination. Once opened, the product should be used within a reasonable timeframe as indicated on the packaging, and any remaining medication after completion of treatment should be properly disposed of rather than saved for potential future use. Medication that appears discolored, has developed an unusual odor, or shows visible signs of degradation should not be administered. When in doubt about product integrity, consult with the prescribing veterinarian or dispensing pharmacy.

Disposal of unused or expired diclazuril should follow local guidelines for veterinary pharmaceutical waste. Many veterinary clinics and pharmacies offer take-back programs for unused medications, providing a convenient and environmentally responsible disposal option. Unused medication should not be discarded in household trash where it might be accessed by children, pets, or wildlife, nor should it be flushed or poured into drains or water systems. Environmental contamination with antiprotozoal compounds, while less concerning than with some other medication classes, should still be minimized through responsible disposal practices. Product packaging may contain specific disposal instructions that should be followed where provided.

Draft breeds including Clydesdales, Percherons, Belgians, and Shires present unique considerations for diclazuril therapy due to their substantially greater body mass compared to light horse breeds. Accurate weight determination becomes particularly important in these breeds, as underestimation of body weight is common and may result in subtherapeutic dosing. Draft horses may weigh between 1,600 and 2,200 pounds or more, requiring proportionally larger medication amounts to achieve appropriate plasma drug concentrations. Veterinarians experienced with draft breeds can provide guidance on accurate weight assessment and appropriate dosing calculations for these gentle giants.

Light horse breeds and warmbloods represent the majority of horses diagnosed with and treated for EPM, partly reflecting their predominant use in athletic disciplines where neurological impairment is more readily detected and of greater competitive consequence. These breeds generally fall within the standard dosing parameters established during drug development and approval. However, certain breeds may have specific health considerations that affect EPM treatment decisions. Thoroughbreds and related breeds used in racing face stringent regulatory requirements regarding medication use, necessitating careful attention to withdrawal times and regulatory compliance.

Ponies and miniature horses require particular attention to dosing precision, as their smaller body size leaves less margin for error in medication calculations. A miniature horse weighing 200 pounds requires substantially less medication than a full-sized horse, and ensuring accurate measurement is essential for both safety and efficacy. These smaller equines may also have metabolic differences that affect drug processing, though specific pharmacokinetic studies in pony and miniature breeds are limited. Veterinary guidance is especially important for EPM treatment in these populations to ensure appropriate therapeutic approaches.

Breed-specific genetic conditions may influence EPM treatment considerations for certain horses. Quarter Horses and related breeds with HYPP, PSSM, or other genetic myopathies may have special monitoring needs during treatment for any illness. Arabian horses with genetic conditions affecting immune function require careful evaluation, as immunocompromise may have contributed to EPM development. Friesians have documented predispositions to certain health conditions that may complicate treatment of concurrent EPM. While no breed-specific contraindications to diclazuril have been established, veterinarians should consider the complete health picture when developing treatment plans for horses of breeds with known genetic predispositions.

Several FDA-approved alternatives exist for EPM treatment, providing veterinarians with options when diclazuril is not appropriate or effective for a particular case. Ponazuril, marketed as Marquis, represents another triazine-class antiprotozoal with demonstrated efficacy against Sarcocystis neurona. The paste formulation of ponazuril offers an alternative administration method for horses that refuse pellet top-dress medications. Some veterinarians have preferences between these agents based on clinical experience, and cases that fail to respond adequately to one triazine may sometimes respond to another, though this approach requires careful veterinary evaluation.

Pyrimethamine-sulfadiazine combination therapy, available as ReBalance, represents a different pharmacological approach to EPM treatment. This combination works through inhibition of folate synthesis in the parasite and may be selected for cases with documented or suspected Neospora hughesi involvement, for horses that cannot tolerate triazine compounds, or based on veterinarian preference and experience. The combination requires twice-daily dosing and has a different side effect profile than the triazine drugs, factors that may influence treatment selection for individual cases.

Supportive therapies often accompany antiprotozoal treatment for EPM and may continue after completion of the primary treatment course. Anti-inflammatory medications, vitamin E supplementation for antioxidant support, and physical rehabilitation protocols may all contribute to optimal outcomes. Joint supplements, digestive support products, and immune-supporting nutraceuticals are frequently administered alongside EPM treatment, though their direct contribution to EPM recovery is not well established. Horse owners should discuss all planned supportive therapies with their veterinarian to ensure a coordinated treatment approach. Any decision to substitute one EPM medication for another should be made only under direct veterinary supervision, as each drug has distinct properties, dosing requirements, and monitoring considerations.